{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:34:03Z","timestamp":1771850043210,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.neuropharm.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T17:02:09Z","timestamp":1485104529000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["In\u00a0vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects"],"prefix":"10.1016","volume":"117","author":[{"given":"Marielle","family":"Delnomdedieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-1644","authenticated-orcid":false,"given":"Adam","family":"Ogden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Ray","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Stenkrona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Duvvuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Al-Tawil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio V.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangram","family":"Nag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Varrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neuropharm.2017.01.016_bib1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2967\/jnumed.113.122895","article-title":"In\u00a0vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654","volume":"55","author":"Barret","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2017.01.016_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00004728-198102000-00027","article-title":"Head fixation device for reproducible position alignment in transmission CT and positron emission tomography","volume":"5","author":"Bergstrom","year":"1981","journal-title":"J.\u00a0Comput. Assist. Tomogr."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.01.016_bib3","first-page":"S104","volume":"153","author":"Chen","year":"2014","journal-title":"Dev. Nov. PET Ligands (PF-04831704 PF-06327104) PDE10A Schizophrenia Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.01.016_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","article-title":"Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited","volume":"30","author":"Cunningham","year":"2010","journal-title":"J.\u00a0Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.01.016_bib5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.01.016_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.01.016_bib7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.01.016_bib8","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"issue":"42","key":"10.1016\/j.neuropharm.2017.01.016_bib9","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.01.016_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-008-0579-2","article-title":"Influence of posture on pharmacokinetics","volume":"65","author":"Queckenberg","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2017.01.016_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.neuropharm.2017.01.016_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.01.016_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.01.016_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2017.01.016_bib15","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dualsubstrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.01.016_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004728-199401000-00023","article-title":"The ECAT EXACT HR: performance of a new high resolution positron scanner","volume":"18","author":"Wienhard","year":"1994","journal-title":"J.\u00a0Comput. Assist. Tomogr."},{"issue":"44","key":"10.1016\/j.neuropharm.2017.01.016_bib17","doi-asserted-by":"crossref","first-page":"15426","DOI":"10.1523\/JNEUROSCI.1148-12.2012","article-title":"A\u00a0novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease","volume":"32","author":"Yu-Taeger","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.01.016_bib18","series-title":"Advancing Phosphodiesterase 10A (PDE10A) inhibitor from bench toclinic","author":"Zaleska","year":"2013"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T19:10:14Z","timestamp":1587409814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817300199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":18,"alternative-id":["S0028390817300199"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}